JISTIC: identification of significant targets in cancer.
BACKGROUND
Cancer is caused through a multistep process, in which a succession of genetic changes, each conferring a competitive advantage for growth and proliferation, leads to the progressive conversion of normal human cells into malignant cancer cells. Interrogation of cancer genomes holds the promise of understanding this process, thus revolutionizing cancer research and treatment. As datasets measuring copy number aberrations in tumors accumulate, a major challenge has become to distinguish between those mutations that drive the cancer versus those passenger mutations that have no effect.


RESULTS
We present JISTIC, a tool for analyzing datasets of genome-wide copy number variation to identify driver aberrations in cancer. JISTIC is an improvement over the widely used GISTIC algorithm. We compared the performance of JISTIC versus GISTIC on a dataset of glioblastoma copy number variation, JISTIC finds 173 significant regions, whereas GISTIC only finds 103 significant regions. Importantly, the additional regions detected by JISTIC are enriched for oncogenes and genes involved in cell-cycle and proliferation.


CONCLUSIONS
JISTIC is an easy-to-install platform independent implementation of GISTIC that outperforms the original algorithm detecting more relevant candidate genes and regions. The software and documentation are freely available and can be found at: http://www.c2b2.columbia.edu/danapeerlab/html/software.html.
Sanchez-Garcia
Felix
F
Department of Computer Science, Columbia University, New York, NY, USA. fs2282@columbia.edu
Akavia
Uri David
UD
Mozes
Eyal
E
Pe'er
Dana
D
D002869:Chromosome Aberrations; D030541:Databases, Genetic; D014644:Genetic Variation; D015894:Genome, Human; D023281:Genomics / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D012984:Software
Clin Cancer Res. 2006 Dec 1;12(23):6937-45
17145811
Bioinformatics. 2004 Dec 12;20(18):3413-22
15381628
J Clin Invest. 2004 Mar;113(6):913-23
15067324
Mol Cell Biol. 2008 Jul;28(14):4629-41
18458058
Br J Cancer. 2008 Dec 16;99(12):2083-7
18985039
Curr Med Chem. 2008;15(25):2559-73
18855679
Biochem Biophys Res Commun. 2008 Feb 1;366(1):226-32
18060868
Nat Genet. 2009 Apr;41(4):465-72
19270706
Cancer Lett. 2009 Jan 8;273(1):140-7
18778892
Cancer Genet Cytogenet. 2009 Jul;192(1):44-7
19480937
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4834-9
19261849
Mol Cell Biol. 2001 Mar;21(5):1854-65
11238922
Genes Dev. 2008 Aug 1;22(15):2028-33
18676808
Mol Cell. 2006 Aug 4;23(3):401-12
16885029
Nat Rev Cancer. 2004 Mar;4(3):177-83
14993899
Nat Genet. 2000 May;25(1):25-9
10802651
PLoS One. 2008 Sep 11;3(9):e3179
18784837
Nature. 2008 Sep 25;455(7212):547-51
18794900
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8
12297621
Nature. 2008 Oct 23;455(7216):1061-8
18772890
Nature. 2007 Dec 6;450(7171):893-8
17982442
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12
18077431
Blood. 2004 Feb 15;103(4):1445-53
14551139
J Biol Chem. 2009 Apr 24;284(17):11279-84
19244252